All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 5, 2021
Home » Blogs » BioWorld Perspectives » It’s About the Patient

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

It’s About the Patient

Dec. 13, 2011
By Mari Serebrov
No Comments

An FDA advisory committee this week gave a half-hearted vote of approval – 9-8, with two abstentions – for Alexza Pharmaceuticals Inc.’s Adasuve (Staccato loxapine). But the vote was conditioned on limiting the inhaled antipsychotic to one dose per day and imposing a much stiffer REMS than what the company had proposed.

While Alexza didn’t feel that much love from the Psychopharmacologic Drugs Advisory Committee (PDAC), it did get enough to bolster its flailing shares and keep hope alive for FDA approval come the Feb. 4 PDUFA date. A day after the lackluster committee performance, Alexza (NASDAQ:ALXA) hit $1, a 60 percent improvement over its Friday closing of 62.5 cents. But as the day waned and the reality of the vote sank in, the share price settled at just under 80 cents Tuesday.

There may have been a lot more love flowing had Alexza not fallen into a trap that’s ensnaring a lot of promising drugs: It forgot its patient.

In focusing on getting drugs developed and approved by an agency more and more averse to risk, drugmakers often try to create the perfect trial setting to showcase the efficacy and “safety” of their investigational drugs. The trouble is patients don’t live in a perfect world.

The real world setting for Adasuve, for instance, is most likely the psychiatric emergency room, but Alexza didn’t test it there. Instead, it recruited subjects through community referrals. Because of a risk of bronchospasms, trial subjects went through intensive screening for asthma and chronic obstructive pulmonary disease. Those with significant pulmonary disease were excluded from the pivotal trials. Subjects also were trained to use the device prior to treatment.

But when acutely agitated patients are brought in to a psychiatric emergency room, they are in no condition to give their medical history, follow directions on use of an inhaler or effectively report respiratory problems they might have as a result of the treatment.

Another fact Alexza forgot about Adasuve’s intended patients is that they have a high rate of smoking, which can lead to respiratory problems. In testing Adasuve, Alexza excluded smokers, for safety reasons, from its Phase I and II trials. As a result of the trial setting and exclusions, the FDA questioned whether the true risks of Adasuve are known.

To ease the FDA’s concerns, Alexza proposed a real-world postmarket study that would, for the first time, compare Adasuve with standard of care instead of placebo. PDAC members rightly commented that this study should have been done to support approval.

Alexza isn’t alone in forgetting the intended patient in an effort to make a drug as attractive as possible. Time after time, advisory committees question sponsors about the lack of relevant study data. While a sponsor could go broke conducting every study a committee suggests, some of them are no-brainers. An antiviral being developed to treat hepatitis C should be tested in patients who also have HIV since the two are often comorbidities. Or a drug intended mostly for a geriatric population should be tested in elderly subjects instead of younger people who might be healthier.

Yet sponsors continue to come to advisory committees with the answers to the wrong questions, hoping that a REMS, a boxed warning or a restricted label will cover the inadequacies of their trials. Instead, they should begin by focusing on the needs, the health and the lifestyle of the intended patients and then design their trials based on those demographics.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 4.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing